secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scilex Holding Co (SCLX)
CIK:        0001820190
Form:       8-K
Filed at:   2024-07-25T23:59:59+00:00
Accession:  0000950170-24-086629
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scilex appoints Annu Navani, M.D. as Class II director and committee member
---------------------------------------------------------------------------

- Appointed Annu Navani, M.D. as Class II director effective July 21, 2024; she will serve on the Commercialization and Transaction Committee.
- Dr. Navani is CEO of Comprehensive Spine and Sports Center and CMO of Boomerang Healthcare; Clinical Professor at Stanford.
- Granted initial stock option for 250,000 shares vesting monthly over 48 months under Non-Employee Director Compensation Policy.
- No family relationships or related-party transactions; standard indemnification agreement entered.
- Press release issued July 23, 2024 announcing the appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1820190/000095017024086629/0000950170-24-086629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1820190/000095017024086629/sclx-20240721.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-086629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer